These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...

“Our study complements these findings by showing, for the first time, that more intensive lifestyle changes may often stop or ...

Blarcasemine met its primary endpoints, improving cognition and function over a four year period in early-stage Alzheimer’s ...

Dementias, like Alzheimer's disease ... In Stages 4 and 5, the individual has moderate symptoms, including memory loss and ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

IGC-M3 targets the disease on four fronts, showing promise in cellular models - POTOMAC, MD / ACCESS Newswire / August 5, 2025 /IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a ...

Alzheimer's disease, communication breakdown, dementia symptoms, end stage dementia, family caregiving, final progression, incontinence, mobility issues, sleep disruption, swallowing difficulties ...

In terms of quality of life, someone 75 years old, retired with significant memory problems, can still have friends and, “a ...

The Alzheimer’s Association has launched a new, free app to help those in the early stages of the disease and their loved ...

IGC-M3 targets the disease on four fronts, showing promise in cellular models - POTOMAC, MD / ACCESS Newswire / August 5, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or ...